155 related articles for article (PubMed ID: 38573494)
1. Establishment of a human ovarian clear cell carcinoma cell line mutant in PIK3CB but not PIK3CA.
Hoshino H; Inoue D; Shinagawa A; Yoshida H; Shigeto S; Matsuda K; Akama TO; Yoshida Y; Kobayashi M
Hum Cell; 2024 Apr; ():. PubMed ID: 38573494
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of a cell line (HCH-1) originating from a human clear cell carcinoma of the ovary.
Yamada T; Hattori K; Satomi H; Okazaki T; Mori H; Hirose Y
J Ovarian Res; 2016 Jun; 9(1):32. PubMed ID: 27259990
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.
Sato S; Itamochi H; Oumi N; Chiba Y; Oishi T; Shimada M; Sato S; Chikumi J; Nonaka M; Kudoh A; Komatsu H; Harada T; Sugiyama T
Hum Cell; 2016 Oct; 29(4):181-7. PubMed ID: 26960408
[TBL] [Abstract][Full Text] [Related]
4. Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1).
Jiang W; Ye S; Xiang L; Yang W; He T; Pei X; Guo L; Yang H
J Ovarian Res; 2018 Jul; 11(1):58. PubMed ID: 29986747
[TBL] [Abstract][Full Text] [Related]
5. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Mod Pathol; 2012 Apr; 25(4):615-24. PubMed ID: 22157930
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
[TBL] [Abstract][Full Text] [Related]
8. Expression of low-sulfated keratan sulfate in non-mucinous ovarian carcinoma.
Hoshino H; Chen YY; Inoue D; Yoshida Y; Khoo KH; Akama TO; Kobayashi M
Glycobiology; 2024 Mar; 34(1):. PubMed ID: 37440446
[TBL] [Abstract][Full Text] [Related]
9. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a clear cell carcinoma cell line, designated NOCC, derived from human ovary.
Ohyama A; Toyomura J; Tachibana T; Isonishi S; Takahashi H; Ishikawa H
Hum Cell; 2016 Oct; 29(4):188-96. PubMed ID: 27541369
[TBL] [Abstract][Full Text] [Related]
11. The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level.
Goldman AR; Bitler BG; Schug Z; Conejo-Garcia JR; Zhang R; Speicher DW
Mol Cell Proteomics; 2016 Nov; 15(11):3348-3360. PubMed ID: 27654507
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma.
Aoki D; Suzuki N; Susumu N; Noda T; Suzuki A; Tamada Y; Higashiguchi A; Oie S; Nozawa S
Hum Cell; 2005 Sep; 18(3):143-6. PubMed ID: 17022146
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
15. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma.
van Niekerk CC; Poels LG; Jap PH; Smeets DF; Thomas CM; Ramaekers FC; Vooijs GP
Int J Cancer; 1988 Jul; 42(1):104-11. PubMed ID: 3292443
[TBL] [Abstract][Full Text] [Related]
17. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
18. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Banerjee S; Stewart J; Porta N; Toms C; Leary A; Lheureux S; Khalique S; Tai J; Attygalle A; Vroobel K; Lord CJ; Natrajan R; Bliss J
Int J Gynecol Cancer; 2021 Nov; 31(11):1471-1475. PubMed ID: 34518240
[TBL] [Abstract][Full Text] [Related]
19. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
Gadducci A; Lanfredini N; Tana R
Gynecol Endocrinol; 2014 Sep; 30(9):612-7. PubMed ID: 24905724
[TBL] [Abstract][Full Text] [Related]
20. [Establishment of a cell line from human ovarian cancer (undifferentiated carcinoma of FIGO classification) and analysis of its cell-biological characteristics and sensitivity to anticancer drugs].
Yoshiya N
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Oct; 38(10):1747-53. PubMed ID: 3782955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
